Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.75 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.75 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | TNKS | O95271 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670860 | 1.00 | HPGD (0.81) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL4650047 | 0.89 | HPGD (1.00) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL21704890 | 0.88 | AKR1C3 (0.71) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL312255 | 0.86 | AKR1C3 (1.00) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL22806648 | 0.85 | HPGD (0.72) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL30933461 | 0.84 | HPGD (0.75) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL9080220 | 0.83 | AKR1C3 (0.72) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL6244185 | 0.83 | HPGD (0.62) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL311588 | 0.82 | HPGD (0.76) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL311714 | 0.82 | HPGD (0.76) | HPGDCYP3A4KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118370833-A | Application of STING agonist in preparation of medicines for inhibiting monkey pox virus | 中国医学科学院医学实验动物研究所 | 2024-07-23 | — | — | CN | claimed |
| CN-117396222-A | Pharmaceutical combination and use thereof | 天津立博美华基因科技有限责任公司 | 2024-01-12 | — | — | CN | claimed |
| CN-116390764-A | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses | 密歇根大学董事会 | 2023-07-04 | — | — | CN | claimed |
| US-20220387470-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-12-08 | — | — | US | claimed |
| EP-3962493-A2 | METHODS OF MODULATING IMMUNE ACTIVITY/LEVEL OF IRF OR STING OR OF TREATING CANCER, COMPRISING THE ADMINISTRATION OF A STING MODULATOR AND/OR PURINERGIC RECEPTOR MODULATOR OR POSTCELLULAR SIGNALING FACTOR | Flagship Pioneering Innovations V, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| US-12397060-B2 | pHLIP®-mediated intracellular delivery of immuno-stimulatory compounds | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3402801-B1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | INNATE TUMOR IMMUNITY INC (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-112672763-B | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2025-03-25 | — | — | CN | disclosed |
| EP-4408480-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118370833-A | Application of STING agonist in preparation of medicines for inhibiting monkey pox virus | 中国医学科学院医学实验动物研究所 | 2024-07-23 | — | — | CN | disclosed |
| CN-113573731-B | Immunopotentiating adjuvant capable of being applied in combination with oil emulsion and foot-and-mouth disease vaccine composition containing same | 大韩民国(动植物检疫局) | 2024-07-12 | — | — | CN | disclosed |
| CN-118043084-A | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2024-05-14 | — | — | CN | disclosed |
| US-20220387470-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022248353-A1 | ADJUVANTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-12-01 | — | — | WO | disclosed |
| US-20220305048-A1 | USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| CN-109451740-B | Cyclic dinucleotides for the treatment of disorders associated with STING activity, such as cancer | 先天肿瘤免疫公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220088208-A1 | PHLIP®-MEDIATED INTRACELLULAR DELIVERY OF IMMUNO-STIMULATORY COMPOUNDS | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3962493-A2 | METHODS OF MODULATING IMMUNE ACTIVITY/LEVEL OF IRF OR STING OR OF TREATING CANCER, COMPRISING THE ADMINISTRATION OF A STING MODULATOR AND/OR PURINERGIC RECEPTOR MODULATOR OR POSTCELLULAR SIGNALING FACTOR | Flagship Pioneering Innovations V, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220031825-A1 | IMMUNOLOGICAL ADJUVANT AND VACCINE COMPOSITION INCLUDING STING AGONIST | QURATIS INC (KR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | HPGD 2044/4885CYP3A4 4530/4885KDM4E 3411/4885 |
| US-20220088208-A1 | PHLIP®-MEDIATED INTRACELLULAR DELIVERY OF IMMUNO-STIMULATORY COMPOUNDS | STING1, MAVS, IRF3 | HPGD 976/4885CYP3A4 4838/4885KDM4E 3697/4885 |
| US-20220387470-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | HPGD 2044/4885CYP3A4 4530/4885KDM4E 3411/4885 |
| US-12397060-B2 | pHLIP®-mediated intracellular delivery of immuno-stimulatory compounds | STING1, MAVS, IRF3 | HPGD 976/4885CYP3A4 4838/4885KDM4E 3697/4885 |
| US-20220305048-A1 | USE OF HEPARIN TO PROMOTE TYPE 1 INTERFERON SIGNALING | IFNAR1, IFNG, STAT1 | HPGD 1162/4885CYP3A4 4406/4885KDM4E 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.